ReviewTherapeutic advances in musculoskeletal disease2018

Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil.

Marcos Renato de Assis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.